Is elevation of N-terminal pro-B-type natriuretic peptide at discharge associated with 2-year composite endpoint of all-cause mortality and heart failure hospitalisation after transcatheter aortic valve implantation? Insights from a multicentre prospective OCEAN-TAVI registry in Japan

What Was Tested

This observational study looks at BNP (Nesiritide).

The aim of this study was to investigate the 2-year prognostic impact of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at discharge following transcatheter aortic valve implantation (TAVI).

Who Took Part

The abstract describes 500 patients taking part.

By PubMed's age tags, the people studied were people over 80, both men and women.

Seven institutions from multicentre, observational registry of symptomatic patients with severe aortic stenosis who undergo TAVI.

The researchers enrolled 500 consecutive patients who underwent TAVI with measurements of NT-proBNP at discharge between 2013 and 2016.

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.

Study patients were stratified into two groups according to survival classification and regression tree (CART) analysis: high versus low NT-proBNP groups.

The impact of high NT-proBNP on a 2-year composite endpoint consisting of all-cause mortality and heart failure hospitalisation was evaluated using a multivariable Cox model.

What Was Measured

Topics PubMed links to this paper include Aortic Valve Stenosis, Biomarkers, Heart Failure, Hospitalization, Incidence, Japan and Mortality.

Author keywords: adult cardiology and valvular heart disease.

What This Means in Plain Language

The paper is a multicenter study of BNP (Nesiritide) in 500 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (BMJ open), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.